Please login to the form below
sleep disorders
This page shows the latest sleep disorders news and features for those working in and with pharma, biotech and healthcare.
Axovant bets on gene therapy with $842.5m Oxford BioMedica deal
Axovant’s lead candidate now is nelotanserin, a 5-HT2a receptor inverse agonist in phase II trials as a treatment for visual hallucinations and sleep disorders in Lewy body dementia and
Latest news
-
After Axovant shock, Roivant pens diabetes deal with Poxel
and sleep disorders in Lewy body dementia and dementia associated with Parkinson’s disease.
-
Axovant joins ever-growing Alzheimer’s failure club
CEO. Aside from the 5-HT6 inhibitor, the biotech is developing a 5-HT2a receptor inverse agonist called nelotanserin in phase II for visual hallucinations and sleep disorders in patients with
-
FDA panel backs sleep pattern drug for blind
Vanda’s Hetlioz intended to improve circadian rhythms in people who cannot see
-
Teva halts development of Nuvigil in bipolar disorder
Shelves plan to expand use of sleep disorder therapy. Teva Pharmaceutical has halted a programme investigating the use of its sleep disorder treatment Nuvigil to treat depression after disappointing late-stage ... sleep disorders, such as sleep apnea or
-
Chasing the cure for Parkinson's disease
Unfortunately, levodopa is associated with long-term motor complications (eg motor fluctuations and dyskinesias), low blood pressure, arrhythmias, gastrointestinal problems, nausea, hair loss, sleep disorders, confusion, anxiety and hallucinations.
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Pharma deals in May 2015
This has proved to be the case following Teva's purchase of Cephalon in May 2011 for $6.2bn which brought Provigil (modafinil for sleep disorders) into the portfolio. ... The paediatric PRV was issued when Cholbam was approved for the treatment of
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Neurodiversity, ADHD and work: Obstacles and opportunities
they generally persist through to adulthood, leading to on average worse educational, occupational, economic, social and relationship outcomes,[3] with higher rates of comorbidities such as mood, anxiety and sleep ... Journal of attention disorders, 16(7)
-
Clark Health Communications unveils new positioning
The agency continues to work on international programmes in multiple areas of women’s health and in prostate cancer, haemophilia, sleep/breathing disorders, health informatics and medical diagnostic services and UK
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
